嗜鉻細胞瘤市場規模、佔有率和成長分析：按治療方法、診斷、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球嗜鉻細胞瘤市值為 15.9 億美元，預計到 2025 年將成長至 16.8 億美元，到 2033 年將成長至 26.4 億美元，在預測期（2026-2033 年）內複合年成長率為 5.8%。

全球嗜鉻細胞瘤市場正經歷顯著成長，這主要得益於監管機構對罕見疾病的獎勵，這些措施鼓勵創新療法的研發。孤兒藥資格認定為研發者提供快速核准流程、稅收優惠和降低財務風險，從而加速兒茶酚胺合成抑制劑等新藥的上市。因此，目前正在進行多項前景可觀的臨床試驗，旨在研發抑制腫瘤去甲腎上腺素釋放的藥物，為手術治療提供替代方案。此外，人工智慧技術透過分析影像數據進行早期檢測、識別基因組突變以實現個人化治療以及簡化治療策略制定，正在改善診斷和治療。隨著這些進步改善患者預後和醫療效率，它們正在刺激進一步的投資並推動市場成長，最終促進新療法的應用。

全球嗜鉻細胞瘤市場成長要素

全球嗜鉻細胞瘤市場的主要促進因素之一是內分泌疾病盛行率的不斷上升，以及人們對該疾病認知的提高和診斷技術的進步。隨著醫療專業人員對嗜鉻細胞瘤的了解不斷加深，早期診斷和治療日益受到重視，從而改善了患者的預後。此外，影像技術和生物標記識別的創新正在改善這種罕見腫瘤的早期檢測和後續觀察，增加了對特效療法的需求。對個人化醫療和個人化治療的日益重視也推動了市場成長，加速了針對嗜鉻細胞瘤患者的有效藥物和治療策略的研發。

全球嗜鉻細胞瘤市場的限制因素

全球嗜鉻細胞瘤市場面臨的主要限制因素是醫療專業人員和公眾對該疾病的認知和了解有限。嗜鉻細胞瘤是一種罕見腫瘤，若未能及時診斷和治療，可能導致嚴重的健康併發症。這種認知不足導致診斷延遲和漏報，進而阻礙了對有效治療方法和篩檢工具的需求。此外，該疾病的複雜性以及對特殊治療的需求，進一步限制了願意承擔嗜鉻細胞瘤診療責任的醫療機構數量，從而影響了整體市場成長。

嗜鉻細胞瘤的全球市場趨勢

全球嗜鉻細胞瘤市場正經歷著向先進影像技術顯著轉變的趨勢，這大大改善了這種罕見腫瘤的診斷和治療。醫療專業人員越來越傾向於採用能夠實現早期檢測和精準定位的先進影像技術，例如使用創新放射性示蹤劑的PET/ 電腦斷層掃描。這種轉變不僅降低了診斷的不確定性，也加速了治療進程，並推動了協作式醫療模式的發展。此外，由於非侵入性治療能夠最大限度地減少不必要的干預，從而節省成本，因此，醫生和保險公司都越來越支持非侵入性治療。為了滿足這一日益成長的需求，影像公司和專業實驗室正在加強研究合作，並透過有針對性的推廣活動來擴展服務範圍。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球嗜鉻細胞瘤市場規模：依治療類型分類

• 外科手術
• 藥物治療
  • α-腎上腺素受體阻斷劑
  • BETA-腎上腺素受體阻斷劑
  • 酪胺酸羥化酶抑制劑
  • 放射性藥物
  • 其他
• 放射性藥物療法
• 標靶治療
• 其他

全球嗜鉻細胞瘤市場規模：依診斷類型分類

• 生物化學檢驗
• 影像檢查
• 基因檢測

全球嗜鉻細胞瘤市場規模：依最終用戶分類

• 醫院
• 專科內分泌中心
• 腫瘤中心
• 學術研究機構

全球嗜鉻細胞瘤市場規模：依分銷管道分類

• 醫院藥房
• 零售藥房
• 專科藥房

全球嗜鉻細胞瘤市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Lantheus Holdings, Inc.
• Novartis AG
• Telix Pharmaceuticals Limited
• Curium Pharma
• GE HealthCare Technologies Inc.
• Siemens Healthineers AG
• ITM Isotope Technologies Munich SE
• Eli Lilly and Company
• Exelixis, Inc.
• Merck KGaA
• Pfizer Inc.
• Bayer AG
• Amgen Inc.
• Fusion Pharmaceuticals Inc.
• RayzeBio, Inc.
• Clarity Pharmaceuticals Ltd.
• Blue Earth Therapeutics Ltd.
• Jubilant Radiopharma
• Perspective Therapeutics, Inc.
• Bristol Myers Squibb

結論與建議

Global Pheochromocytoma Market size was valued at USD 1.59 Billion in 2024 and is poised to grow from USD 1.68 Billion in 2025 to USD 2.64 Billion by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

The global pheochromocytoma market is experiencing notable growth driven by regulatory support for rare-disease incentives, which promote the development of innovative treatments. The orphan-drug designation provides developers with expedited review pathways and tax benefits that reduce financial risks, facilitating the introduction of new agents, such as catecholamine-synthesis inhibitors. This has resulted in an enriched pipeline with promising clinical trials for drugs that lower intra-tumoral norepinephrine release, presenting alternatives to surgical interventions. Furthermore, AI technologies enhance both diagnosis and treatment by analyzing imaging data for early detection, identifying genomic mutations for personalized therapies, and streamlining treatment recommendations. As these advancements improve patient outcomes and healthcare efficiency, they stimulate further investment and propel market growth, leading to increased adoption of new therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pheochromocytoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pheochromocytoma Market Segments Analysis

Global pheochromocytoma market is segmented by treatment type, diagnosis type, end user, distribution channel and region. Based on treatment type, the market is segmented into Surgery, Drug Therapy, Radiopharmaceutical Therapy, Targeted Therapy and Others. Based on diagnosis type, the market is segmented into Biochemical Tests, Imaging Tests and Genetic Testing. Based on end user, the market is segmented into Hospitals, Specialty Endocrinology Centers, Oncology Centers and Academic & Research Institutes. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pheochromocytoma Market

One of the key market drivers for the global pheochromocytoma market is the increasing prevalence of endocrine disorders coupled with growing awareness and advancements in diagnostic technologies. As healthcare professionals become more knowledgeable about pheochromocytoma, timely diagnoses and treatments are prioritized, leading to improved patient outcomes. Additionally, innovations in imaging techniques and biomarker identification enhance early detection and monitoring of this rare tumor, driving demand for specialized treatment options. The rising focus on personalized medicine and tailored therapies further propels market growth by encouraging the development of effective drugs and care strategies specifically for pheochromocytoma patients.

Restraints in the Global Pheochromocytoma Market

A significant market restraint for the global pheochromocytoma market is the limited awareness and understanding of the condition among healthcare professionals and the general public. Pheochromocytoma is a rare tumor that can lead to serious health complications if not diagnosed and treated timely. This lack of awareness results in delayed diagnoses and underreporting, which hampers the demand for effective therapies and screening tools. Additionally, the complexity of the disorder, coupled with the need for specialized treatment options, further limits the availability of healthcare providers willing to engage in the management of pheochromocytoma, impacting overall market growth.

Market Trends of the Global Pheochromocytoma Market

The Global Pheochromocytoma market is witnessing a notable trend towards the adoption of precision imaging techniques, significantly enhancing the diagnosis and treatment of this rare tumor. Healthcare professionals increasingly favor advanced imaging modalities, such as PET/CT scans with innovative radiotracers, which facilitate earlier detection and precise localization. This evolution not only mitigates diagnostic uncertainty but also expedites the treatment process and encourages collaborative care models. Additionally, the emphasis on non-invasive procedures resonates with both physicians and payers, as these methods potentially reduce costs by minimizing unnecessary interventions. Consequently, imaging companies and specialized laboratories are ramping up research partnerships and expanding their service capabilities to cater to this rising demand through targeted outreach initiatives.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Pheochromocytoma Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Surgery
• Drug Therapy
  • Alpha-Adrenergic Blockers
  • Beta-Adrenergic Blockers
  • Tyrosine Hydroxylase Inhibitors
  • Radiopharmaceuticals
  • Others
• Radiopharmaceutical Therapy
• Targeted Therapy
• Others

Global Pheochromocytoma Market Size by Diagnosis Type & CAGR (2026-2033)

• Market Overview
• Biochemical Tests
• Imaging Tests
• Genetic Testing

Global Pheochromocytoma Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Endocrinology Centers
• Oncology Centers
• Academic & Research Institutes

Global Pheochromocytoma Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies

Global Pheochromocytoma Market Size & CAGR (2026-2033)

• North America (Treatment Type, Diagnosis Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Diagnosis Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Diagnosis Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Diagnosis Type, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Diagnosis Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lantheus Holdings, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Telix Pharmaceuticals Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curium Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE HealthCare Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ITM Isotope Technologies Munich SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fusion Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RayzeBio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clarity Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Blue Earth Therapeutics Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Radiopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perspective Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations